Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?

Shah D, Brown S, Hagemeier N, Zheng S, Kyle A, Pryor J, Dankhara N, Singh P.

Springerplus. 2016 Jun 23;5(1):854. doi: 10.1186/s40064-016-2576-8. eCollection 2016.

2.

The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.

Wiegand TJ.

J Med Toxicol. 2016 Mar;12(1):64-70. doi: 10.1007/s13181-015-0518-4.

PMID:
26574020
3.

A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report.

Goodman DJ, Milliken CU, Theiler RN, Nordstrom BR, Akerman SC.

J Dual Diagn. 2015;11(3-4):248-57. doi: 10.1080/15504263.2015.1104484.

4.

Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.

Fitting S, Zou S, El-Hage N, Suzuki M, Paris JJ, Schier CJ, Rodríguez JW, Rodriguez M, Knapp PE, Hauser KF.

Curr HIV Res. 2014;12(6):424-34.

5.

Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.

Joseph D, Schobelock MJ, Riesenberg RR, Vince BD, Webster LR, Adeniji A, Elgadi M, Huang F.

Antimicrob Agents Chemother. 2015 Jan;59(1):498-504. doi: 10.1128/AAC.04046-14. Epub 2014 Nov 10.

6.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

7.

Medication-assisted treatment for opioid addiction: methadone and buprenorphine.

Saxon AJ, Hser YI, Woody G, Ling W.

J Food Drug Anal. 2013 Dec;21(4):S69-S72.

8.

Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.

Masson CL, Rainey PM, Moody DE, McCance-Katz EF.

Am J Addict. 2014 Jan-Feb;23(1):34-40. doi: 10.1111/j.1521-0391.2013.12052.x. Epub 2013 Jun 10.

9.

Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

Blum K, Oscar-Berman M, Femino J, Waite RL, Benya L, Giordano J, Borsten J, Downs WB, Braverman ER, Loehmann R, Dushaj K, Han D, Simpatico T, Hauser M, Barh D, McLaughlin T.

J Addict Res Ther. 2013 Apr 23;4(2). doi: 10.4172/2155-6105.1000146.

10.

A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.

Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC.

J Pharmacol Exp Ther. 2014 Feb;348(2):217-26. doi: 10.1124/jpet.113.209478. Epub 2013 Nov 13.

11.

Initiation of buprenorphine during incarceration and retention in treatment upon release.

Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD.

J Subst Abuse Treat. 2013 Aug;45(2):222-6. doi: 10.1016/j.jsat.2013.02.005. Epub 2013 Mar 27.

12.

Update on the clinical use of buprenorphine: in opioid-related disorders.

Ducharme S, Fraser R, Gill K.

Can Fam Physician. 2012 Jan;58(1):37-41. Review.

13.

Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Blum K, Chen TJ, Bailey J, Bowirrat A, Femino J, Chen AL, Simpatico T, Morse S, Giordano J, Damle U, Kerner M, Braverman ER, Fornari F, Downs BW, Rector C, Barh D, Oscar-Berman M.

Mol Neurobiol. 2011 Dec;44(3):250-68. doi: 10.1007/s12035-011-8206-0. Epub 2011 Sep 24.

14.

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Yokell MA, Zaller ND, Green TC, Rich JD.

Curr Drug Abuse Rev. 2011 Mar;4(1):28-41. Review.

15.

Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells.

Li L, Hassan HE, Tolson AH, Ferguson SS, Eddington ND, Wang H.

J Pharmacol Exp Ther. 2010 Dec;335(3):562-71. doi: 10.1124/jpet.110.173187. Epub 2010 Sep 9.

16.

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):511-4.

18.

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH.

Drug Alcohol Depend. 2009 Dec 1;105(3):234-9. doi: 10.1016/j.drugalcdep.2009.07.007. Epub 2009 Sep 1.

19.
20.

Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.

Kacinko SL, Jones HE, Johnson RE, Choo RE, Concheiro-Guisan M, Huestis MA.

Clin Chem. 2009 Jun;55(6):1177-87. doi: 10.1373/clinchem.2008.113712. Epub 2009 Mar 26.

Items per page

Supplemental Content

Write to the Help Desk